Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015:2015:435141.
doi: 10.1155/2015/435141. Epub 2015 Aug 25.

Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV

Simona Di Mario  1 , Vittorio Basevi  1 , Pier Luigi Lopalco  2 , Sara Balduzzi  3 , Roberto D'Amico  3 , Nicola Magrini  4
Affiliations
Meta-Analysis

Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV

Simona Di Mario et al. J Immunol Res. 2015.

Erratum in

Abstract

Background: When the bivalent and the quadrivalent HPV vaccines were marketed they were presented as having comparable efficacy against cervical cancer. Differences between the vaccines are HPV types included and formulation of the adjuvant.

Method: A systematic review was conducted to assess the efficacy of the two vaccines against cervical cancer. Outcomes considered were CIN2+, CIN3+, and AIS.

Results: Nine reports (38,419 women) were included. At enrollment mean age of women was 20 years, 90% had negative cytology, and 80% were seronegative and/or DNA negative for HPV 16 or 18 (naïve women). In the TVC-naïve, VE against CIN2+ was 58% (95% CI: 35, 72); heterogeneity was detected, VE being 65% (95% CI: 54, 74) for the bivalent and 43% (95% CI: 23, 57) for the quadrivalent. VE against CIN3+ was 78% (95% CI: <0, 97); heterogeneity was substantial, VE being 93% (95% CI: 77, 98) for the bivalent and 43% (95% CI: 12, 63) for the quadrivalent. VE in the TVC was much lower. No sufficient data were available on AIS.

Conclusions: In naïve girls bivalent vaccine shows higher efficacy, even if the number of events detected is low. In women already infected the benefit of the vaccination seems negligible.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection flowchart.
Figure 2
Figure 2
Vaccine efficacy against CIN2+ lesions, in total vaccine (a) and total vaccine naïve cohort (b), any HPV type.
Figure 3
Figure 3
Vaccine efficacy against CIN3+ lesions, in total vaccine (a) and total vaccine naïve cohort (b), any HPV type.
See this image and copyright information in PMC

References

    1. Clifford G., Franceschi S., Diaz M., Muñoz N., Villa L. L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24(supplement 3):S26–S34. doi: 10.1016/j.vaccine.2006.05.026. - DOI - PubMed
    1. Sargent A., Bailey A., Almonte M., et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. British Journal of Cancer. 2008;98(10):1704–1709. doi: 10.1038/sj.bjc.6604324. - DOI - PMC - PubMed
    1. Sankaranarayanan R., Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Practice and Research: Clinical Obstetrics and Gynaecology. 2006;20(2):207–225. doi: 10.1016/j.bpobgyn.2005.10.007. - DOI - PubMed
    1. Schiffman M., Castle P. E. The promise of global cervical-cancer prevention. The New England Journal of Medicine. 2005;353(20):2101–2104. doi: 10.1056/nejmp058171. - DOI - PubMed
    1. Moscicki A.-B., Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. The Journal of the American Medical Association. 2001;285(23):2995–3002. doi: 10.1001/jama.285.23.2995. - DOI - PubMed

MeSH terms

Substances